These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 29679478)

  • 1. Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate-to-severe plaque psoriasis.
    Anil Kumar MS; Papp K; Tainaka R; Valluri U; Wang X; Zhu T; Schwabe C
    Biopharm Drug Dispos; 2018 May; 39(5):245-255. PubMed ID: 29679478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, phase 1b study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of bleselumab, a fully human, anti-CD40 monoclonal antibody, in kidney transplantation.
    Vincenti F; Klintmalm G; Yang H; Ram Peddi V; Blahunka P; Conkle A; Santos V; Holman J
    Am J Transplant; 2020 Jan; 20(1):172-180. PubMed ID: 31397943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-In-Human, Phase 1, Randomized, Dose-Escalation Trial with Recombinant Anti-IL-20 Monoclonal Antibody in Patients with Psoriasis.
    Gottlieb AB; Krueger JG; Sandberg Lundblad M; Göthberg M; Skolnick BE
    PLoS One; 2015; 10(8):e0134703. PubMed ID: 26252485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability, pharmacokinetics and efficacy of HB0017, a humanized monoclonal antibody that targets interleukin-17A, in healthy participants and patients with moderate-to-severe plaque psoriasis.
    Jiang C; Du Y; Liu X; Wang J; Ge C; Xu J; Wang S; Li B; Zhu G; Zhang W; Qian Q; Ma C; Zhu X; Zhan Y; Yang Y
    Br J Dermatol; 2023 Dec; 190(1):28-36. PubMed ID: 37669307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study.
    Nemoto O; Hirose K; Shibata S; Li K; Kubo H
    Br J Dermatol; 2018 Mar; 178(3):689-696. PubMed ID: 29222947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis.
    Papp KA; Gooderham MJ; Girard G; Raman M; Strout V
    J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):1324-1332. PubMed ID: 28556418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
    Dubertret L; Sterry W; Bos JD; Chimenti S; Shumack S; Larsen CG; Shear NH; Papp KA;
    Br J Dermatol; 2006 Jul; 155(1):170-81. PubMed ID: 16792770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, Safety and Pharmacokinetics of IL-17 Monoclonal Antibody Injection (AK111) in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blinded, Placebo-Controlled Phase Ib Multidose Escalation Clinical Study.
    Jiang C; Zhou H; Zhang W; Xia Y; Li B; Ni X; Wang G; Zhang W; Chen B; He Z; Zhang M; Chen R; Jin H; Deng L
    Dermatol Ther (Heidelb); 2023 Feb; 13(2):555-567. PubMed ID: 36566344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
    Papp KA; Leonardi C; Menter A; Ortonne JP; Krueger JG; Kricorian G; Aras G; Li J; Russell CB; Thompson EH; Baumgartner S
    N Engl J Med; 2012 Mar; 366(13):1181-9. PubMed ID: 22455412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis.
    Papp K; Pariser D; Catlin M; Wierz G; Ball G; Akinlade B; Zeiher B; Krueger JG
    Br J Dermatol; 2015 Sep; 173(3):767-76. PubMed ID: 25704750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
    Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
    Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
    Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
    Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin 17A/F nanobody, in moderate-to-severe psoriasis.
    Svecova D; Lubell MW; Casset-Semanaz F; Mackenzie H; Grenningloh R; Krueger JG
    J Am Acad Dermatol; 2019 Jul; 81(1):196-203. PubMed ID: 30926369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A).
    Callis Duffin K; Bagel J; Bukhalo M; Mercado Clement IJ; Choi SL; Zhao F; Gill A; Pangallo B; Shuler C; Mallbris L; Jackson K
    J Eur Acad Dermatol Venereol; 2017 Jan; 31(1):107-113. PubMed ID: 27500949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.
    Leonardi C; Langley RG; Papp K; Tyring SK; Wasel N; Vender R; Unnebrink K; Gupta SR; Valdecantos WC; Bagel J
    Arch Dermatol; 2011 Apr; 147(4):429-36. PubMed ID: 21173304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial.
    Ohtsuki M; Fujita H; Watanabe M; Suzaki K; Flack M; Huang X; Kitamura S; Valdes J; Igarashi A
    J Dermatol; 2019 Aug; 46(8):686-694. PubMed ID: 31237727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.
    Leonardi C; Matheson R; Zachariae C; Cameron G; Li L; Edson-Heredia E; Braun D; Banerjee S
    N Engl J Med; 2012 Mar; 366(13):1190-9. PubMed ID: 22455413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial.
    Gottlieb AB; Griffiths CE; Ho VC; Lahfa M; Mrowietz U; Murrell DF; Ortonne JP; Todd G; Cherill R; Marks I; Emady-Azar S; Paul CF;
    Br J Dermatol; 2005 Jun; 152(6):1219-27. PubMed ID: 15948985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.